Recent

% | $
Quotes you view appear here for quick access.

OCATA THERAPEUTICS, INC. Message Board

factsfood 54 posts  |  Last Activity: May 26, 2016 4:39 PM Member since: Jan 9, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Annual Meeting

    by richs375 May 26, 2016 3:44 PM
    factsfood factsfood May 26, 2016 4:39 PM Flag

    Thank you for sharing this information.

  • factsfood by factsfood May 25, 2016 12:18 PM Flag

    Based on the PPS behavior today it is quite clear to me that the only thing that will increase share value is positive news related to trial results. The interview while nice, accomplished nothing other that I now have insight into the thinking about the requested authorization for new shares. House cleaning......... I don't think so. They have some 12 million shares of fire power remaining now. If they deliver on trial results and get the PPS up to the $20 range or more, 5 million of the exiting shares offered for sale will provide some $100 million of new cash for funding programs and the NSS launch. I can't believe he mentioned acquisitions as a possibility for needing shares. That's ludicrous to say the least. Let's get this company moving faster first as I am now very suspicious about the new shares request, more so than before.

  • Reply to

    Today's NVIV Buying

    by factsfood May 24, 2016 2:29 PM
    factsfood factsfood May 24, 2016 4:38 PM Flag

    Anticipation of positive trial results, bullish sentiment all around, likely positive analyst reports perhaps due out post new shares offering, small hurdle to meet FDA criteria (67% of the way with 13 patients remaining with needing only one to be successful for meeting trial criteria. It's a good bet based on all of the aforementioned.

    Sentiment: Strong Buy

  • factsfood by factsfood May 24, 2016 2:29 PM Flag

    While volume is on the low side with most trades involving 100 shares, the buying is being controlled with large volume offered on the sell side and small volumes of 100 shares on the buy side with a downtick. Whenever a bid comes in for 500 or more buy side shares, the price goes up. Bottom line, buyers in action today.

  • Reply to

    Next week will be a good week

    by biotrader922 May 15, 2016 1:51 PM
    factsfood factsfood May 16, 2016 10:04 AM Flag

    The Squire trials and results could very likely have an impact on NVIV similar to that of ICPT about 18 mos ago. Let's hope as there has never been a remedy for SCI that has been so positive, no matter how limited the patient improvements are. Something at this point raises the level of hope dramatically, all before using the neural stem cells in combination with the scaffold. As to longs, exciting times for sure.

    Sentiment: Strong Buy

  • Looking at the trading pattern it appears that over 90% of the NVIV trades are for 100 share lots that are placed automatically using programmed trading. The manipulators never rest.

    Sentiment: Strong Buy

  • Reply to

    Size of SCI Market?

    by foosfund May 6, 2016 11:09 AM
    factsfood factsfood May 6, 2016 3:11 PM Flag

    Probably has more to do with the number of facilities/physicians trained to performed the required surgery and candidate pool that must also meet certain criteria. I would imagine with so many new trial sites added in the last six weeks, we should truly start to see a pick-up in patients real soon.

  • Reply to

    Added more at $5.40

    by binh15945 May 5, 2016 1:19 PM
    factsfood factsfood May 5, 2016 2:16 PM Flag

    Good for you! Keep putting in the low ball bids playing into the hands of the shorts that distort the true value of NVIV in the market place.

  • Reply to

    factsfood

    by envy_vo May 5, 2016 1:03 PM
    factsfood factsfood May 5, 2016 2:11 PM Flag

    Inspire: Sincere thanks for your time and thoughtful response. I am familiar with the aspects and negatives of toxic financing as a finance professional in publicly traded entities for over 30 years. The OCAT problem for me was a high entry point, pre-toxic financing. Additionally, when things finally started to look up with management changes and settlements, the science was progressing very favorably. In time, with the clinical trials advancing, the PPS would have moved up, and financing via additional sale of shares post-the 100/1 reverse split would have been more beneficial for all concerned. It was the way the thing was managed that caught all by surprise, especially by a new management team that fed press releases to the public to maintain interest. It was only after new employment contracts were dangled in front of the OCAT team together with buckets of funds for continued research and stock options that made them bite for the deal.
    In the case of NVIV, I am certainly not against management at all, and have tremendous respect and confidence in the science. My issue is more identified with timing of the request. We have funds to carry us through to the end of 2017. By that time we will already have results on the 20 patients in our trials, likely by mid 2017 when the next annual meeting takes place and hopefully the stock has increased substantially, assuming continued success of the trial. The big factor becomes how much dilution do we want to take on and when. I simply say that one year out, the dilution will be significantly less give an expected PPS of $30 or more. Hope I helped my argument against the authorizatoin of so many new shares in your mind at least.

    Sentiment: Strong Buy

  • factsfood by factsfood May 5, 2016 12:23 PM Flag

    For those NVIV shareholders who are yet to vote: Presently, insiders and institutions own some 35% of shares outstanding. If this new authorization goes through, the 35% will surly grow to over 50% and that will be the end of the Long Term small investors, just as was the case with OCATA, the very promising stem cell company bought for peanuts by a Japanese firm after the stock was beat down to below $5.00 per share following an increase in authorized shares and fund raise. The Japanese firm Astellas followed this move with an offer of $8.50 per share and given the institutions were in at the $5.00 range for only a few months, they made an enormous return for a brief period of ownership and pushed the vote after three attempts to just over the 50% required shareholder approval threshold. THIS COULD VERY WELL PLAY OUT AGAIN FOR NVIV, CLASSIC MANAGEMENT/WALL ST. MANIPULATION TO ENRICH THEMSELVES AND TO HELL WITH THE OTHER NON-INSTITUTIONAL SHAREHOLDERS. Less

  • Reply to

    Voting "yes"

    by envy_vo May 2, 2016 3:05 PM
    factsfood factsfood May 5, 2016 11:15 AM Flag

    Presently, insiders and institutions own some 35% of shares outstanding. If this new authorization goes through, the 35% will surly grow to over 50% and that will be the end of the Long Term small investors, just as was the case with OCATA, the very promising stem cell company bought for peanuts by a Japanese firm after the stock was beat down to below $5.00 per share following an increase in authorized shares and fund raise. The Japanese firm Astellas followed this move with an offer of $8.50 per share and given the institutions were in at the $5.00 range for only a few months, they made an enormous return for a brief period of ownership and pushed the vote after three attempts to just over the 50% required shareholder approval threshold. THIS COULD VERY WELL PLAY OUT AGAIN FOR NVIV, CLASSIC MANAGEMENT/WALL ST. MANIPULATION TO ENRICH THEMSELVES AND TO HELL WITH THE OTHER NON-INSTITUTIONAL SHAREHOLDERS.

  • Reply to

    Voting "yes"

    by envy_vo May 2, 2016 3:05 PM
    factsfood factsfood May 4, 2016 2:34 PM Flag

    The only people that will be vigilant with our equity is us, the shareholders. Haven't you seen enough carnage at the small retail investor level over the years where nothing matters except the big players making quick returns at any cost and management teams enriching themselves at the expense of the shareholders they represent and to hell with the most important graduate business school teaching as to a management's responsibility which is "Increase the value of the shareholders ownership". I hope you wake up from your dreamland soon.

    Sentiment: Strong Buy

  • Scared rabbits in diapers are making it easy for the short sellers who sold above $6.00 per share to cover their position as these bargain basement prices. Part of the LT investor problems include not only the short sellers and day traders, but the investors who can't hold their water. Too bad for most of us in for the Longer Term. I keep averaging down.

    Sentiment: Strong Buy

  • Reply to

    Regarding Authorized shares...

    by envy_vo May 2, 2016 5:20 PM
    factsfood factsfood May 3, 2016 10:57 AM Flag

    I am one of the OCAT survivors. Yes, toxic financing is available everywhere, but in the case of OCAT, they survived the lethal doses and it was the management team that ultimately sold out to 1) realize their gains from free stock grants that totaled in the millions of shares after shareholders approved an increase in authorized shares that tipped the scale of ownership from Long Term investors in support of the science, to institutions and management that together gave them some 45% of the stock ownership. When it came time to sell out, the management team first negotiated long term employment contracts for themselves to remain in charge of OCAT as a wholly-owned subsidiary of Astellas. Moreover, it took three tries to get the 50% of the voting shares that were needed for the merger to go through in a demonstration of resistance from the shareholders who lost millions at the hands of the corrupt management team that lied about clinical trial results, held back information to name a few of their misdeeds. So go ahead all those who want to approve the increase in authorized shares that I believe to be very unnecessary at this time with so much success to date reported on the Inspire program. If the increase in shares is approved, get ready for a royal shafting from the Management Team and Board of Directors. It happens more than 50% of the time.

    Sentiment: Strong Buy

  • Reply to

    Voting "yes"

    by envy_vo May 2, 2016 3:05 PM
    factsfood factsfood May 2, 2016 4:44 PM Flag

    They have enough shares authorized now and money to last until the end of 2017. If they deliver on their press release timing, the stock should be above $25 PPS in early 2017 and then I will approve an increase in authorized shares. Not a day sooner.

  • Reply to

    VOTE YES TO INCREASE AUTHORIZED SHARES

    by reality_check_l Apr 26, 2016 8:47 AM
    factsfood factsfood Apr 29, 2016 11:34 AM Flag

    Just voted my 35,000 shares against.

  • Reply to

    Looks like a sell-off but it is actually

    by factsfood Apr 29, 2016 11:09 AM
    factsfood factsfood Apr 29, 2016 11:32 AM Flag

    You are clearly correct and an astute market expert on such matters I am sure.

  • Managed buying by the shorts and manipulators looking at the individual trades and volume, many 100 share sells on the down tick, with large purchases of 1,000 shares or more at the newly established low points. Shorts are at work doing managed covering.

    Sentiment: Strong Buy

  • Reply to

    Beginning To Think...

    by elcaribes Apr 28, 2016 1:58 PM
    factsfood factsfood Apr 28, 2016 2:11 PM Flag

    While I fully agree with most of your post, I do think there is a good chance for a rocket launch in the not too distant future. Hopefully we will get lucky.

  • With the prospects for the NVIV scaffold so bright, why are we not in the teens in terms of our stock PPS? Lack of good PR, lack of analyst coverage, vermin market manipulators. We will see this change for the better, real soon.

    Sentiment: Strong Buy